ANFOE 4000

Anfoe 4000IU injection contains active ingredients such as Recombinant human erythropoietin alfa/epoetin alfa. This medication is classified as an erythropoiesis-stimulating agent (ESA). It is used to treat anemia resulting from chronic kidney disease (CKD), cancer chemotherapy, or HIV treatment with zidovudine. Additionally, it helps decrease the necessity for red blood cell transfusions in patients who are at a heightened risk of blood loss due to scheduled surgeries or other medical procedures.

Anfoe 4000IU injection is contraindicated in individuals with hypersensitivity to the drug or any of its components, uncontrolled hypertension, active thrombotic microangiopathy (TMA), pure red cell aplasia (PRCA), uncontrolled seizures, pregnancy, or breastfeeding. Caution is advised when administering this medication to patients with a history of blood clots, cardiovascular disease, stroke, kidney disease, liver disease, thalassemia, sickle cell anemia, myelodysplastic syndrome, leukemia, or cancer. It should only be prescribed to children under 18 if the potential benefits surpass the risks. Older adults receiving this medication should be monitored closely for any adverse effects. Prior to initiating treatment with Anfoe 4000IU injection, it is essential to discuss the associated risks and benefits with your healthcare provider.